-
Loading metrics
Open Access
Peer-reviewed
Research Article
Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera
-
Manfred Kraus ,
Contributed equally to this work with: Manfred Kraus, Yuxun Wang
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Yuxun Wang ,
Contributed equally to this work with: Manfred Kraus, Yuxun Wang
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Dan Aleksandrowicz,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Eric Bachman,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Alexander A. Szewczak,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Deborah Walker,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Lin Xu,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Melaney Bouthillette,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Kaleen M. Childers,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Brian Dolinski,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Andrew M. Haidle,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Johnny Kopinja,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Linda Lee,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Jongwon Lim,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Kevin D. Little,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Yanhong Ma,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Anjili Mathur,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Jan-Rung Mo,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Erin O’Hare,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Ryan D. Otte,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Brandon M. Taoka,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Wenxian Wang,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Hong Yin,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Anna A. Zabierek,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Weisheng Zhang,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Shuxia Zhao,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Joe Zhu,
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ -
Jonathan R. Young ,
* E-mail: christopher_marshall3@merck.com (CGM); jonathan_young@merck.com (JRY)
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ - [ ... ],
-
C. Gary Marshall
* E-mail: christopher_marshall3@merck.com (CGM); jonathan_young@merck.com (JRY)
Affiliation Departments of DMPK, in vitro Sciences, in vivo Sciences, Medicinal Chemistry, Basic Pharmaceutical Sciences and Oncology, Merck Research Laboratories, Boston, Massachusetts, United States of America
⨯ - [ view all ]
- [ view less ]
Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera
- Manfred Kraus,
- Yuxun Wang,
- Dan Aleksandrowicz,
- Eric Bachman,
- Alexander A. Szewczak,
- Deborah Walker,
- Lin Xu,
- Melaney Bouthillette,
- Kaleen M. Childers,
- Brian Dolinski
- Published: May 18, 2012
- https://doi.org/10.1371/journal.pone.0037207